1. Cell Cycle/DNA Damage
    Autophagy
  2. DNA/RNA Synthesis
    Autophagy

Actinomycin D (Synonyms: Dactinomycin; Actinomycin IV)

Cat. No.: HY-17559 Purity: 99.89%
Data Sheet SDS Handling Instructions

Actinomycin D inhibits DNA repair with IC50 of 0.42 μM.

For research use only. We do not sell to patients.
Actinomycin D Chemical Structure

Actinomycin D Chemical Structure

CAS No. : 50-76-0

Size Price Stock Quantity
10 mM * 1 mL in DMSO $124 In-stock
5 mg $52 In-stock
10 mg $90 In-stock
50 mg $395 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

    Actinomycin D purchased from MCE. Usage Cited in: Cancer Lett. 2017 Aug 18;407:45-56.

    UM-SCC6 and UM-SCC6H cells are treated with Actinomycin D (ActD 5 μg/mL) for the indicated times. The IGF2 mRNA level is measured by RT-PCR.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Actinomycin D inhibits DNA repair with IC50 of 0.42 μM.

    IC50 & Target

    IC50: 0.42 μM (DNA repair)[1]

    In Vitro

    Actinomycin D is an inhibitor of DNA transcription and replication[1]. Actinomycin D markedly reduces the vascular smooth muscle cells (SMC) proliferation via the inhibition of BrdU incorporation at 80 nM. This is further supported by the G1-phase arrest using a flowcytometric analysis. Actinomycin D is extremely potent with an inhibitory concentration IC50 at 0.4 nM, whereas the lethal dose LD50 is at 260 microM. The protein expression levels of proliferating cell nuclear antigen (PCNA), focal adhesion kinase (FAK), and Raf are all suppressed by Actinomycin D. Extracellular signal-regulated kinases (Erk) involved in cell-cycle arrest are found to increase by Actinomycin D[2].

    In Vivo

    The pluronic gel containing 80 nM and 80μM Actinomycin D is applied topically to surround the rat carotid adventitia, the thickness of neointima is substantially reduced (45 and 55%, respectively)[2]. Mice in the Actinomycin D and fludarabine group lives significantly longer than the control group with P values of <0.001 and 0.007, respectively. Interestingly, single treatment with Actinomycin D is superior to fludarabine regarding overall survival (P=0.026)[3].

    Clinical Trial
    NCT Number Sponsor Condition Start Date Phase
    NCT02639650 Weiguo Lv|First Affiliated Hospital of Zhongshan Medical University|Shandong University|Huazhong University of Science and Technology|Women's Hospital School Of Medicine Zhejiang University Gestational Trophoblastic Neoplasms March 2016 Phase 3
    NCT02639650 Weiguo Lv|First Affiliated Hospital of Zhongshan Medical University|Shandong University|Huazhong University of Science and Technology|Women's Hospital School Of Medicine Zhejiang University Gestational Trophoblastic Neoplasms March 2016 Phase 3
    NCT01323517 Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb Melanoma February 2011 Phase 2
    NCT00003702 Gynecologic Oncology Group|Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Good Prognosis Metastatic Gestational Trophoblastic Tumor|Hydatidiform Mole|Non-Metastatic Gestational Trophoblastic Tumor|Uterine Corpus Choriocarcinoma June 1999 Phase 3
    NCT00003688 Gynecologic Oncology Group|National Cancer Institute (NCI) Gestational Trophoblastic Tumor October 1999 Phase 2
    NCT00075582 Children's Oncology Group|National Cancer Institute (NCI) Adult Rhabdomyosarcoma|Embryonal Childhood Rhabdomyosarcoma|Embryonal-botryoid Childhood Rhabdomyosarcoma|Previously Untreated Childhood Rhabdomyosarcoma September 2004 Phase 3
    NCT01535053 Gynecologic Oncology Group|National Cancer Institute (NCI) Choriocarcinoma|FIGO Stage I Gestational Trophoblastic Tumor|FIGO Stage II Gestational Trophoblastic Tumor|FIGO Stage III Gestational Trophoblastic Tumor|Hydatidiform Mole June 2012 Phase 3
    NCT00245089 Japan Rhabdomyosarcoma Study Group|National Cancer Institute (NCI) Sarcoma May 2004 Phase 2
    NCT00354835 Children's Oncology Group|National Cancer Institute (NCI) Adult Malignant Mesenchymoma|Adult Rhabdomyosarcoma|Childhood Alveolar Rhabdomyosarcoma|Childhood Botryoid-Type Embryonal Rhabdomyosarcoma|Childhood Embryonal Rhabdomyosarcoma|Childhood Malignant Mesenchymoma|Non-Metastatic Childhood Soft Tissue Sarcoma|Stage I Adult Soft Tissue Sarcoma|Stage II Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Untreated Childhood Rhabdomyosarcoma December 2006 Phase 3
    NCT00352534 Children's Oncology Group|National Cancer Institute (NCI) Stage I Wilms Tumor|Stage II Wilms Tumor|Stage III Wilms Tumor October 2006 Phase 3
    NCT00245141 Japan Rhabdomyosarcoma Study Group|National Cancer Institute (NCI) Sarcoma May 2004 Phase 2
    NCT01531244 Washington University School of Medicine Melanoma December 2014 Phase 1|Phase 2
    NCT02567435 National Cancer Institute (NCI) Alveolar Rhabdomyosarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma|Rhabdomyosarcoma|Sclerosing Rhabdomyosarcoma|Spindle Cell Rhabdomyosarcoma|Untreated Childhood Rhabdomyosarcoma May 23, 2016 Phase 3
    NCT00003958 Children's Oncology Group|National Cancer Institute (NCI) Adult Malignant Mesenchymoma|Adult Rhabdomyosarcoma|Alveolar Childhood Rhabdomyosarcoma|Childhood Malignant Mesenchymoma|Embryonal Childhood Rhabdomyosarcoma|Embryonal-botryoid Childhood Rhabdomyosarcoma|Nonmetastatic Childhood Soft Tissue Sarcoma|Previously Untreated Childhood Rhabdomyosarcoma|Stage I Adult Soft Tissue Sarcoma|Stage II Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma September 2002 Phase 3
    NCT00004250 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Melanoma (Skin)|Sarcoma August 1999 Phase 2
    NCT00354744 Children's Oncology Group|National Cancer Institute (NCI) Sarcoma July 2006 Phase 3
    NCT01014767 Tufts Medical Center Brain Cancer|Choroid Plexus Tumors November 2009 Phase 3
    NCT00002995 Children's Oncology Group|National Cancer Institute (NCI) Sarcoma August 1997 Phase 3
    NCT01871766 St. Jude Children's Research Hospital Rhabdomyosarcoma December 4, 2013 Phase 2
    NCT01464606 Children's Hospitals and Clinics of Minnesota Pleuropulmonary Blastoma September 2011
    NCT00003804 University of Leicester|National Cancer Institute (NCI) Kidney Cancer July 1993 Phase 3
    NCT01055314 National Cancer Institute (NCI) Adult Rhabdomyosarcoma|Childhood Alveolar Rhabdomyosarcoma|Childhood Embryonal Rhabdomyosarcoma|Metastatic Childhood Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma|Untreated Childhood Rhabdomyosarcoma January 2010 Phase 2
    NCT00084838 Dana-Farber Cancer Institute|National Cancer Institute (NCI) Central Nervous System Tumor, Pediatric February 2003 Phase 2
    NCT00072280 Children's Oncology Group|National Cancer Institute (NCI) Sarcoma November 2004 Phase 2
    NCT00335556 Children's Oncology Group|National Cancer Institute (NCI) Childhood Renal Cell Carcinoma|Clear Cell Renal Cell Carcinoma|Clear Cell Sarcoma of the Kidney|Papillary Renal Cell Carcinoma|Rhabdoid Tumor of the Kidney|Stage I Renal Cell Cancer|Stage I Renal Wilms Tumor|Stage II Renal Cell Cancer|Stage II Renal Wilms Tumor|Stage III Renal Cell Cancer|Stage III Renal Wilms Tumor|Stage IV Renal Cell Cancer|Stage IV Renal Wilms Tumor June 2006 Phase 2
    NCT00020566 University of Leicester|National Cancer Institute (NCI)|Children's Cancer and Leukaemia Group|Societe Francaise Oncologie Pediatrique|European Organisation for Research and Treatment of Cancer - EORTC|Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria|Swiss Group for Clinical Cancer Research|EBMT Solid Tumors Working Party|Children's Oncology Group Sarcoma February 2001 Phase 3
    NCT00945009 Children's Oncology Group|National Cancer Institute (NCI) Adult Renal Wilms Tumor|Beckwith-Wiedemann Syndrome|Childhood Renal Wilms Tumor|Diffuse Hyperplastic Perilobar Nephroblastomatosis|Hemihypertrophy|Stage I Renal Wilms Tumor|Stage II Renal Wilms Tumor|Stage III Renal Wilms Tumor|Stage IV Renal Wilms Tumor|Stage V Renal Wilms Tumor July 2009 Phase 3
    NCT00002611 Children's Oncology Group|National Cancer Institute (NCI) Kidney Cancer July 1995 Phase 3
    NCT00002610 Children's Oncology Group|National Cancer Institute (NCI) Kidney Cancer January 1996 Phase 3
    NCT00003955 Children's Oncology Group|National Cancer Institute (NCI) Sarcoma September 1999 Phase 2
    NCT00379340 Children's Oncology Group|National Cancer Institute (NCI) Stage III Wilms Tumor With Loss of Heterozygosity (LOH) for 1p and 16q|Stage IV Wilms Tumor February 2007 Phase 3
    NCT00379457 European Paediatric Soft Tissue Sarcoma Study Group|Italian Association for Pediatric Hematology Oncology|Children's Cancer and Leukaemia Group|Dutch Childhood Oncology Group|National Cancer Institute (NCI) Sarcoma June 2006 Phase 3
    NCT00047138 University of Leicester|Societe Francaise Oncologie Pediatrique|Children's Cancer and Leukaemia Group|Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI) Kidney Cancer January 2001 Phase 3
    NCT00025441 Societe Internationale d'Oncologie Pediatrique|Children's Cancer and Leukaemia Group|Societe Francaise Oncologie Pediatrique|National Cancer Institute (NCI) Ovarian Cancer|Sarcoma|Small Intestine Cancer November 1998 Phase 2
    NCT00025103 Children's Cancer and Leukaemia Group|National Cancer Institute (NCI) Kidney Cancer May 2001 Phase 2
    NCT00002898 Societe Internationale d'Oncologie Pediatrique|National Cancer Institute (NCI) Childhood Malignant Fibrous Histiocytoma of Bone|Sarcoma January 1995 Phase 3
    NCT00002766 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Leukemia|Lymphoma March 1996 Phase 3
    NCT00002516 University Hospital Muenster|Medical Research Council|National Cancer Institute (NCI) Sarcoma July 1992 Phase 3
    NCT00002489 Memorial Sloan Kettering Cancer Center Extragonadal Germ Cell Tumor|Ovarian Cancer October 1991 Phase 2
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 0.7965 mL 3.9827 mL 7.9655 mL
    5 mM 0.1593 mL 0.7965 mL 1.5931 mL
    10 mM 0.0797 mL 0.3983 mL 0.7965 mL
    Kinase Assay
    [1]

    Actinomycin D is co-incubated for 3 h at 30°C with a reaction mixture containing: 120 mg of a whole-cell extract of HeLa cells, 70 mM KCl, 0.4 mM each of dGTP, dCTP, dATP, and digoxygenylated-dUTP in reaction buffer containing 40mM Hepes-KOH (pH 7.6), 5 mM MgCl2, 0.5 mM Dithiotreitol, 2 mM EGTA, 10 mM phosphocreatine, 50 mg/mL creatine phosphate, and 360 mg/mL of bovine serum albumin. During this reaction, DNA damage is recognized and the excised patches are replaced by neosynthesized DNA fragments. Throughout this DNA synthesis, digoxygenylated-dUMPs are incorporated. The DNA repair reaction is stopped by three washes[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [3]

    Actinomycin D is prepared in phosphate-buffered saline (PBS) (Mice)[3].

    Mice[3]
    The original Eμ-TCL1a transgenic mice have been backcrossed to C57BL/6 mice for >9 generations.The C57BL/6 wild-type mice are engrafted with tumor cells from Eμ-TCL-1 transgenic mice. The percentage of CD5+/CD19+ cells in the peripheral blood is routinely checked in mice by taking blood from the tail vein and analyzing it via flow cytometry. When the percentage of tumor cells in the peripheral blood reached 40-60%, treatment is started. Actinomycin D (0.06 mg/kg by 10 days) is applied daily via i.p. injections. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    1255.42

    Formula

    C₆₂H₈₆N₁₂O₁₆

    CAS No.

    50-76-0

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 27 mg/mL; DMSO: 250 mg/mL (Need ultrasonic); Methanol: 6.2 mg/mL; Methanol: 20 mg/mL (Need ultrasonic); H2O: < 12.5 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 99.89%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Actinomycin D
    Cat. No.:
    HY-17559
    Quantity: